14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.87 $1.65 Tuesday, 23rd Apr 2024 ADAP stock ended at $1.14. This is 12.87% more than the trading day before Monday, 22nd Apr 2024. During the day the stock fluctuated 15.42% from a day low at $1.01 to a day high of $1.16.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Apr 23, 2024 $1.04 $1.16 $1.01 $1.14 1 130 972
Apr 22, 2024 $0.99 $1.08 $0.95 $1.01 694 153
Apr 19, 2024 $0.92 $1.08 $0.92 $0.98 1 475 459
Apr 18, 2024 $0.97 $0.99 $0.87 $0.90 3 323 777
Apr 17, 2024 $1.02 $1.05 $0.93 $0.99 1 221 844
Apr 16, 2024 $1.20 $1.20 $0.98 $1.03 1 224 075
Apr 15, 2024 $1.20 $1.21 $1.05 $1.05 1 322 411
Apr 12, 2024 $1.20 $1.28 $1.13 $1.16 3 033 667
Apr 11, 2024 $1.28 $1.34 $1.26 $1.29 869 563
Apr 10, 2024 $1.33 $1.33 $1.25 $1.27 1 449 671
Apr 09, 2024 $1.36 $1.41 $1.35 $1.37 717 427
Apr 08, 2024 $1.40 $1.40 $1.33 $1.36 1 018 208
Apr 05, 2024 $1.39 $1.42 $1.32 $1.37 1 204 906
Apr 04, 2024 $1.41 $1.45 $1.35 $1.35 774 904
Apr 03, 2024 $1.40 $1.42 $1.35 $1.38 1 628 372
Apr 02, 2024 $1.46 $1.46 $1.36 $1.40 1 110 910
Apr 01, 2024 $1.55 $1.55 $1.45 $1.47 1 333 977
Mar 28, 2024 $1.65 $1.65 $1.53 $1.58 1 066 010
Mar 27, 2024 $1.55 $1.63 $1.47 $1.58 1 180 018
Mar 26, 2024 $1.45 $1.57 $1.38 $1.52 1 193 755
Mar 25, 2024 $1.45 $1.56 $1.42 $1.44 1 173 516
Mar 22, 2024 $1.34 $1.48 $1.32 $1.44 1 663 925
Mar 21, 2024 $1.29 $1.40 $1.29 $1.34 1 146 245
Mar 20, 2024 $1.44 $1.44 $1.24 $1.33 3 076 279
Mar 19, 2024 $1.45 $1.52 $1.38 $1.41 1 171 164
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT